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Abstract
Pancreatic cancer is a deadly disease, and new therapeutic targets are urgently needed. We previously identified DNA
amplification at 7q21-q22 in pancreatic cancer cell lines. Now, by high-resolution genomic profiling of human pancreatic
cancer cell lines and human tumors (engrafted in immunodeficient mice to enrich the cancer epithelial fraction), we define a
325 Kb minimal amplicon spanning SMURF1, an E3 ubiquitin ligase and known negative regulator of transforming growth
factor b (TGFb) growth inhibitory signaling. SMURF1 amplification was confirmed in primary human pancreatic cancers by
fluorescence in situ hybridization (FISH), where 4 of 95 cases (4.2%) exhibited amplification. By RNA interference (RNAi),
knockdown of SMURF1 in a human pancreatic cancer line with focal amplification (AsPC-1) did not alter cell growth, but led
to reduced cell invasion and anchorage-independent growth. Interestingly, this effect was not mediated through altered
TGFb signaling, assayed by transcriptional reporter. Finally, overexpression of SMURF1 (but not a catalytic mutant) led to
loss of contact inhibition in NIH-3T3 mouse embryo fibroblast cells. Together, these findings identify SMURF1 as an amplified
oncogene driving multiple tumorigenic phenotypes in pancreatic cancer, and provide a new druggable target for
molecularly directed therapy.
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Introduction
Pancreatic ductal adenocarcinoma (hereafter, pancreatic can-
cer) is nearly always fatal, with a five year survival rate less than
5% [1]. It is often disseminated at diagnosis, and can metastasize
widely. Early detection can improve survival, but surgical resection
is rarely curative [2]. Pancreatic cancer is also largely resistant to
conventional chemotherapy. Therefore, new therapies are urgent-
ly needed. In particularly, it will be important to discover and
validate new targets for molecularly-directed therapy.
The molecular genetics of pancreatic cancer are in part known
[3,4]. Somatic activating mutations of KRAS (sometimes occurring
with gene amplification) are found in .90% of pancreatic cancers.
Also common are inactivating mutations/deletions of tumor
suppressors CDKN2A (.95% of cancers), TP53 (50–75%), and
SMAD4 (also known as DPC4) (55%), an effector of TGFb-
mediated growth inhibition. Other gene mutations, each occurring
in less than 5% of cancers, impact these and other core cancer
signaling pathways [5].
Genomic profiling studies, by array-based comparative genomic
hybridization (array CGH), have begun to catalogue DNA
amplifications and deletions, pinpointing and revealing novel
pancreatic cancer genes (e.g. [6,7]). Among altered loci, we and
others previously identified 7q21-q22 as a site recurrently
amplified in pancreatic cancer [8–13]. Here, we narrow that
locus, and characterize SMURF1 as an oncogene product
promoting cell invasion and anchorage-independent growth.
Results
SMURF1 is focally amplified in pancreatic cancer
We had previously identified recurrent amplification at 7q21-q22
in pancreatic cancer cell lines, using CGH on cDNA microarrays
[12]. To further delimit the amplicon, and pinpoint the resident
oncogene(s), we now carried out additional genomic profiling of a
collection of 22 pancreatic cancer cell lines and 58 early-passage
pancreatic cancer xenografts, using high-resolution 244K Agilent
CGH arrays. The 7q21-q22 locus was focally amplified (tumor/
normalratios.3-fold)in1of22(4.5%)celllines(AsPC-1),andin1of
58 (2%) xenografts. Including lower-level gains (ratios .1.3 fold),
gain/amplification spanning 7q21-q22 was found in 6 of 22 (27%)
cell lines, and in 19 of 58 (33%) xenografts.
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genomic profiles that were particularly informative in delimiting
the amplicon boundaries within 7q21-q22 (Fig. 1A). The smallest
common region of gain spanned just 325 Kb within cytoband
7q22.1, and contained just two RefSeq [14] genes, SMURF1
(SMAD specific E3 ubiquitin protein ligase) and KPNA7
(karyopherin alpha 7). SMURF1 is a known inhibitor of TGFb
signaling (by promoting degradation of its receptor TGFbRI, and
signaling mediator SMAD4 [15,16]), a pathway frequently
disrupted in pancreatic cancer. Given an obvious connection to
pancreatic carcinogenesis, we therefore focused subsequent efforts
on SMURF1.
Consistent with an oncogenic role, SMURF1 transcript
(measured by microarray) was significantly elevated in cell lines/
xenografts with 7q22.1 gain/amplification (as were several co-
amplified neighboring genes) (Fig. 1B). To evaluate SMURF1
amplification in primary pancreatic tumors, we also carried out
FISH on a tissue microarray containing 105 pancreatic cancer
cases. Four of 95 (4.2%) evaluable cases exhibited SMURF1
amplification (locus/centromere ratio .2.5) (Fig. 1C), comparable
to our CGH findings for early-passage xenografts. We were unable
to identify a suitable antibody and staining conditions to evaluate
SMURF1 expression by immunohistochemistry.
SMURF1 amplification promotes cell invasion and
anchorage-independent growth
To evaluate possible oncogenic functions of SMURF1, we first
used RNAi to knockdown SMURF1 expression in the relevant
context of gene amplification, using AsPC-1 cells. Transfection of
four different small interfering RNAs (siRNAs), or a pool of the
four together, each led to reduced SMURF1 protein levels (by
Western blot), compared to a non-targeting siRNA pool (Fig. 2A).
Knockdown of SMURF1 did not alter cell proliferation, measured
by WST-1 assay (Fig. 2B,C), and by BrdU incorporation (Fig. 2D),
but led to significantly decreased cell invasion through Matrigel,
measured by Boyden chamber assay (Fig. 2E). Decreased invasion
was seen with each of the four siRNAs targeting distinct SMURF1
sequences, while the growth rate of the cells remained unchanged
within the same time period (Fig. 2C), strongly supporting the
specific role of SMURF1 in the invasiveness phenotype.
Given its known, antagonistic function in the TGFb pathway,
we also sought to evaluate the effect of SMURF1 knockdown on
TGFb signaling, using a TGFb responsive transcriptional reporter
(p3TP-Lux) [17]. Knockdown of SMURF1 did not enhance
TGFb pathway-mediated transcription in AsPC-1 cells (Fig. 2F).
Of note, however, AsPC-1 cells (like most pancreatic cancers)
harbor a mutated SMAD4, here SMAD4 (R100T) [18], charac-
terized to be inactivating [19,20]. Therefore, AsPC-1 cells are
likely incapable of a TGFb pathway transcriptional response.
More generally, these findings suggest that the main effect(s) of
SMURF1 amplification/overexpression are likely mediated
through pathways distinct from TGFb signaling.
To evaluate longer-term phenotypes, we also stably transfected
a short hairpin RNA (shRNA) targeting SMURF1. Stable
knockdown of SMURF1 in AsPC-1 cells, confirmed by Western
blot (Fig. 3A), significantly reduced anchorage independent growth
(soft agar colonies), compared to a non-targeting shRNA control
(Fig. 3B).
We also sought to evaluate the effect of siRNA knockdown in
other pancreatic cancer cell lines. We chose two cell lines, BxPC-3
cells which (like AsPC-1 cells and most pancreatic tumors) have
mutated SMAD4 (here by homozygous deletion) [21], and Hs700T
cells which are wildtype for SMAD4 and have an intact TGFb
growth-inhibitory pathway (Fig. S1). Notably, neither of these lines
harbors focal amplification of SMURF1 (AsPC-1 cells are the only
established line with focal amplification), nor elevated SMURF1
protein levels (Fig. 4A). Knockdown of SMURF1 (validated by
Western blot; Fig. 4B) led to modestly reduced cell proliferation in
BxPC-3 cells (Fig. 4C), and more so in TGFb-growth inhibitory
pathway-intact Hs700T cells (Fig. 4D). SMURF1 knockdown also
resulted in reduced cell invasion in BxPC-3 cells (Fig. 4E), though
not significantly so. However, given that SMURF1 is neither
focally amplified nor overexpressed in these lines, a simple
explanation for the discordant phenotypes (compared to AsPC-1)
is that SMURF1 may not function as an oncogenic driver in these
cell contexts.
Finally, in complementary, overexpression studies, we trans-
fected SMURF1 cDNA (expressed from a CMV promoter) into
NIH-3T3 mouse fibroblasts. Overexpression of SMURF1, con-
firmed by Western blot (Fig. 5A), led to a significant loss of contact
inhibition (i.e. increased foci), compared to a vector control
(Fig. 5B). Notably, transfection of a catalytically-inactive mutant of
SMURF1 (C699A) [22] did not reduce contact inhibition (Fig. 4B),
indicating that this oncogenic activity is dependent on the E3
ubiquitin protein ligase activity of SMURF1.
Discussion
Here, we set out to pinpoint and discover the oncogene driving
7q21-q22 amplification in pancreatic cancer. High-resolution
genomic profiling of pancreatic cancer cell lines and early-passage
xenografts defined a 325 Kb minimal amplicon spanning
SMURF1. Transcript levels of SMURF1 were elevated in
specimens with gain/amplification, and by FISH we confirmed
SMURF1 amplification in primary pancreatic cancers. Using
complementary approaches of knockdown (in focally-amplified
AsPC-1 cells) and overexpression (in NIH-3T3 cells), we
determined that SMURF1 amplification/overexpression does not
alter cell proliferation, but promotes cell invasion, anchorage-
independent growth, and loss of contact inhibition, of which at
least the latter is dependent on its catalytic activity.
SMURF1 was initially an intriguing oncogene candidate
because of its known connection to TGFb signaling. The TGFb
pathway, at least early in tumor development, is growth sup-
pressive [23]. Normally, TGFb binds to its receptors (TGFbRI,
TGFbRII), leading to the phosphorylation of signal transducers
SMAD2/SMAD3, which then shuttle to the nucleus and in
complex with SMAD4 mediate transcription. Key transcriptional
responses include induction of CDKN2B (p15Ink4b) and CDKN1A
(p21Cip1), and repression of MYC, together leading to G1 cell-
cycle arrest. The TGFb growth suppressive pathway is commonly
disrupted in pancreatic cancer, most often through mutation/
deletion of SMAD4, but also through inactivation/loss of TGFbRI
and TGFbRII [4].
SMURF1 is a HECT-domain E3 ubiquitin ligase (E3 ubiquitin
ligases carry out the third and substrate-specific step in protein
ubiquitination). SMURF1 promotes the nuclear export of TGFb
pathway inhibitor SMAD7 (increasing its availability), and the
destruction of TGFbRI and SMAD4 (through ubiquitination-
mediated degradation) [15,16]. All these activities should serve to
antagonize TGFb signaling, and together provide a strong
rationale for SMURF1 amplification/overexpression in pancreatic
cancer. It was notable then, that SMURF1 knockdown in AsPC-1
cells did not enhance TGFb-pathway transcription (though
perhaps not surprising, given the inactivating mutation of SMAD4).
Therefore, the oncogenic activities of SMURF1 must act at least in
part independently of its functions in TGFb signaling (at least at
the pathway level of SMAD4). To this end, SMURF1 has also
SMURF1 Amplification in Pancreatic Cancer
PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e23924Figure 1. Focal amplification of 7q22.1 in pancreatic cancer spans SMURF1. (A) A minimal amplicon is defined by four pancreatic cancer
specimens (AsPC-1 and three xenografts). Starting from bottom: chr 7 ideogram; Heatmap of DNA copy number (red indicates gain) for the four
specimens across the 7q21-q22 region (91–101 Mb); Scatter plot of DNA copy number log2 ratios across 7q21.3-q22.1 (96–100 Mb), overlaid with the
cghFLasso [34] called ratios (red line); Screen shot of the corresponding locus from the UCSC genome browser. The dashed lines bracket the 325 Kb
minimal amplicon, which spans SMURF1.( B) SMURF1 is overexpressed when gained/amplified. Box plots show 25
th,5 0
th (median) and 75
th percentile
transcript levels (assayed by Agilent 44K array) for specimens with (red) or without (gray) 7q21-q22 gain, for SMURF1 and its nearest gene neighbors.
Note, KPNA7 was not represented on the array. *, P,0.05; **, P,0.01; ***, P,0.001 (Mann-Whitney U-test). (C) FISH reveals SMURF1 amplification in
primary pancreatic cancers. Shown are two pancreatic cancers with SMURF1 amplification (center, and right), along with a non-amplified control
(BxPC3 cells, left). SMURF1 locus probe (red); control chr 7 centromere (CRP7) probe (green).
doi:10.1371/journal.pone.0023924.g001
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during epithelial-mesenchymal transition [24], and focal adhesions
(by degradation of talin heads) to potentiate cell migration [25].
Additional studies should clarify the key SMURF1 substrates
linked to invasiveness and anchorage-independent growth in
pancreatic cancers with 7q22 amplification.
During the progress of this work, two other studies character-
ized the 7q21-q22 amplicon in pancreatic cancer. Suzuki et al. [26]
by genomic profiling of cell lines identified the amplicon in AsPC-
1 cells, with the amplicon peak spanning 11 genes. Further efforts
focused on two genes, TRRAP and SMURF1, with significantly
elevated expression when amplified. However, in contrast to our
study, they reported that knockdown of SMURF1 inhibited AsPC-
1 cell proliferation. Notably, though, they evaluated only one
siRNA. Given our results that four independent siRNAs knocked
down SMURF1 levels comparably and decreased invasion without
affecting cell proliferation, we suggest that their finding might
reflect a non-specific or specific off-target RNAi effect. Indeed,
growth inhibition is a common non-specific effect, triggered by a
type I interferon response to siRNA [27]. Suzuki et al. went on to
Figure 2. SMURF1 knockdown in amplified AsPC-1 cells reduces invasion but not growth. (A) Four different siRNAs targeting SMURF1,
and a pool of all four, lead to reduced SMURF1 levels (by Western blot) compared to a non-targeting control siRNA pool). Residual SMURF1 levels,
here normalized to GAPDH, are indicated. (B) SMURF1 knockdown (using siRNA pool) does not reduce cell proliferation/viability, measured by WST1
assay, and done in triplicate (mean +/2 1SD shown). (C) SMURF1 knockdown using four different siRNAs does not significantly alter cell proliferation/
viability, measured three days post transfection. Done in triplicate (mean +/2 1SD shown). (D) SMURF1 knockdown does not reduce cell-cycle
progression (S-phase), measured by BrdU incorporation (1.5 hr and 4 hr pulse labeling), done in triplicate (mean +/2 1 SD shown). (E) SMURF1
knockdown (using siRNA pool and individual siRNAs) inhibits cell invasion through Matrigel. Boyden chamber assay done in triplicate and harvested
three days post transfection (mean +/2 1SD shown); *, P,0.05 (Student’s t-test). (F) SMURF1 knockdown does not enhance TGFb pathway-mediated
transcription. AsPC-1 cells were co-transfected with siRNAs and p3TP-Lux reporter, done in triplicate, and firefly/Renilla luciferase ratios shown (mean
+/2 1SD shown). Panc1 cells (with wildtype SMAD4) +/2 TGFb serve as a positive control.
doi:10.1371/journal.pone.0023924.g002
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lines enhanced colony growth on tissue culture plastic. Nonethe-
less, our findings based on knockdown in the physiologically-
relevant context of focal SMURF1 amplification suggest that the
main oncogenic function of SMURF1 relates to promoting cell
invasiveness rather than proliferation.
In another recent study, Laurila et al. [28] by FISH analysis of
cell lines delimited the 7q21-q22 amplicon to 0.77 Mb spanning
10 genes (including SMURF1), but focused their efforts on ARPC1A
and ARPC1B, subunits of the Arp2/3 complex functioning in actin
polymerization. Using RNAi, they found that knockdown of either
reduced cell motility, and knockdown of ARPC1A also reduced cell
invasion. Though our minimal amplicon excluded ARPC1A and
ARPC1B, it is nonetheless possible that their amplification
contributes to motility/invasion in tumors where they are
amplified. It is not uncommon to find multiple driver oncogenes
within tumor amplicons (e.g. ref. [29]). Indeed, our own studies do
not resolve whether KPNA7, within our 325 Kb minimal
amplicon, might also have an oncogenic role (along with
SMURF1).
To summarize, by genomic profiling and functional analysis we
identified SMURF1 as an amplified oncogene driving cell
invasiveness in pancreatic cancer. Perhaps of most significance,
as an enzyme SMURF1 represents a tractable drug target. Other
E3 ubiquitin ligases have been linked to cancer, and because of
their substrate specificity E3 ubiquitin ligases are thought to be
attractive targets for therapy [30]. Indeed, several small molecule
inhibitors (including against MDM2, a regulator of TP53) are
presently being evaluated [31]. Our findings identify SMURF1 as
a possible new target for molecularly-directed therapy against the
devastating disease of pancreatic cancer.
Materials and Methods
Specimens
Pancreatic cancer cell lines, described previously [12], and
NIH-3T3 cells were obtained from the American Type Culture
Collection (Manassas, VA). Pancreatic cancer xenografts, which
effectively enrich the tumor epithelial fraction for DNA analysis,
were generated as described [32] at the Johns Hopkins Hospital,
with approval from the Institutional Review Board (IRB) (protocol
ID 05-04-14-02) and Animal Care and Use Committee (protocol
ID MO05M466). Briefly, a 1 mm
3 piece of the primary tumor was
soaked in Matrigel (Collaborative Biomedical Research), then
implanted subcutaneously in a nu/nu mouse. Engrafted tumors
were harvested when they reached 1–2 cm in diameter, and tumor
cell enrichment confirmed by H&E-stained frozen section. DNA
and RNA were isolated using the Qiagen (Valencia, CA) AllPrep
kit. Eleven of the 48 xenografts were previously profiled by lower-
resolution CGH on cDNA arrays [6].
Array CGH
CGH was done using Agilent (Santa Clara, CA) catalogue 244K
CGH arrays. DNAs were labeled as described [33], then
hybridized (vs. a pool of eight sex-matched normal leukocyte
DNAs) following the manufacturer’s instructions. Arrays were
scanned using an Agilent G2505B scanner, and data extracted and
normalized using Agilent Feature Extraction software (version 9.1)
with default settings. Copy number alterations were called using
cghFLasso [34], and low-level gains and higher-level ampli-
fications defined by cghFLasso tumor/normal ratios .1.3 and
.3.0, respectively. CGH data detailed herein are available at
GEO (GSE19852); a complete description of the dataset is in
preparation.
Expression profiling
Expression profiling was done using Agilent catalogue 44K
Whole Human Genome arrays. RNAs were labeled using the
Quick Amp Labeling kit (Agilent), then hybridized (vs. a universal
RNA reference pool of 11 cancer cell lines [35]) following the
manufacturer’s instructions. After scanning and data extraction (as
above), expression data were normalized (mean-centered) by array
and by gene, and mean-centered log2 ratios reported.
FISH
A tissue microarray containing 105 pancreatic ductal adeno-
carcinoma cases (archived at Stanford University, and used with
Figure 3. Knockdown of amplified SMURF1 in AsPC-1 cells
reduces anchorage-independent growth. (A) A stably transduced
shRNA targeting SMURF1 leads to reduced SMURF1 levels (by Western
blot) compared to a non-targeting control shRNA. Residual SMURF1
levels, here normalized to GAPDH, are indicated. (B) Stable SMURF1
knockdown reduces anchorage-independent growth (i.e. soft agar
colonies). Assay done in triplicate (mean +/2 1SD shown); *, P,0.05
(Student’s t-test).
doi:10.1371/journal.pone.0023924.g003
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FISH were performed using Vysis (Downers Grove, Illinois)
reagents according to the manufacturer’s protocols. A locus-
specific BAC mapping to SMURF1 at 7q22.1 (RP11-62N3;
BACPAC Resources Centre, Oakland, CA) was labeled with
SpectrumOrange, and co-hybridized with SpectrumGreen-la-
beled chr 7 centromere probe (CEP7; Vysis). Slides were
counterstained with DAPI, and imaged using an Olympus
BX51 fluorescence microscope with Applied Imaging (San Jose,
CA) Cytovision 3.0 software. Twenty-five tumor cells were scored
per case, and amplification defined as an average SMURF1/
CEP7 ratio .2.5.
Figure 4. Analysis of SMURF1 knockdown in other pancreatic cancer lines. (A) Western blot analysis of endogenous SMURF1 protein levels
in a panel of pancreatic cancer cell lines. Note that SMURF1 is highly expressed only in the 7q22.1-amplified AsPC-1 cell line. Two different exposures
of the SMURF1 blot are shown; GAPDH serves as a loading control. (B) Western blot verification of SMURF1 knockdown (by SMURF1-targeting siRNA
pool, compared to non-targeting control siRNA pool) in BxPC-3 and Hs700T cells. (C) Cell proliferation/viability assayed (by WST-1) in BxPC-3 cells
following SMURF1 siRNA-mediated knockdown (compared to non-targeting control). Assay done in triplicate (mean +/2 1SD shown); *, P,0.05
(Student’s t-test). (D) Cell proliferation/viability assayed in Hs700T cells, as above. (E) Cell invasion assayed (by Boyden chamber) in BxPC-3 cells
following SMURF1 knockdown (compared to non-targeting control). Assay done in triplicate (mean +/2 1SD shown). Note, the reduced proliferation
observed with SMURF1 knockdown in Hs700T cells precluded an assay of cell invasion (where invaded cell numbers at 72 hrs are influenced by
doubling times).
doi:10.1371/journal.pone.0023924.g004
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On-TARGETplus siRNAs targeting SMURF1, along with a
negative control siRNA pool (ON-TARGETplus siCONTROL
Non-targeting Pool), were obtained from Dharmacon (Lafayette,
CO). Sequences of siRNAs are listed in Table S1. AsPC-1 cells
were grown at 37uC in complete media of RPMI-1640 (Invitro-
gen, Carlsbad, CA), 10% FBS, 50 U/ml penicillin, and 50 U/ml
streptomycin. For transfection, 150,000 cells were seeded per 6-
well plate well, and transfected using Lipofectamine 2000 reagent
(Invitrogen) according to the manufacturer’s protocol. Cells were
transfected with a final concentration of 50 nM siRNA for 6 hrs.
Western blot
Cells were lysed in 16RIPA buffer supplemented as described
[6]. Forty mg total protein lysate was electrophoresed on a 4–15%
polyacrylamide gel, then transferred to PVDF membrane and
blocked in TBST-T with 5% dry milk. Antibodies were used as
follows: anti-SMURF1 rabbit polyclonal antibody (H-60; Santa
Cruz Biotechnology, Santa Cruz, CA) at 1:500 dilution; anti-
GAPDH rabbit polyclonal antibody (Santa Cruz Biotechnology) at
1:5,000 dilution; HRP-conjugated anti-rabbit IgG (Pierce, Rock-
ford, IL) at 1:20,000 dilution. Detection was done using an ECL
kit (GE Healthcare, Piscataway, NJ), and intensities quantified by
densitometry using Scion Image software (Scion Corporation,
Fredrick, MD).
Cell growth and invasion assays
Cell proliferation/viability was quantified by colorimetry based
on the metabolic cleavage of the tetrazolium salt WST-1 in viable
cells, according to the manufacturer’s protocol (Roche, Indianap-
olis, IN). BrdU incorporation was determined by colorimetric
ELISA using the BrdU Cell Proliferation Assay, according to the
manufacturer’s protocol (Cell Signaling Technology, Danvers,
MA). Invasion was quantified by Boyden chamber assay (BD
Biosciences, San Jose, CA). Briefly, 24 hrs after transfection,
50,000 cells were plated into 24-well Matrigel-coated inserts with a
0.5% to 10% FBS gradient. Seventy-two hrs later, cells were fixed,
stained with crystal violet, and cells traversing the membrane
counted. All assays were done as triplicate transfections, and all
experiments were repeated at least once with similar results.
TGFb transcriptional reporter assay
Cells were co-transfected with 4 mg p3TP-Lux (Addgene,
Cambridge, MA), a TGFb responsive firefly luciferase reporter
containing three consecutive TPA response elements (TREs) and a
portion of the plasminogen activator inhibitor 1 (PAI-1) promoter
region [17], along with 0.4 mg pRL-TK (Promega, Madison, WI)
expressing Renilla luciferase as an internal normalization control.
Luciferase activity was assayed 48 hrs after transfection (by
Lipofectamine 2000) using the dual luciferase reporter assay
system (Promega, Madison, WI). Reporter activity is expressed as
the ratio of firefly/Renilla. Assays were done as triplicate
transfections, and repeated at least once with similar results.
Anchorage-independent growth
A pGIPZ shRNAmir construct targeting SMURF1
(V2LHS_229724), along with a non-targeting pGIPZ shRNAmir
control, were obtained from Open Biosystems (Huntsville, AL). To
create stably-transduced AsPC-1 cell pools, lentiviral constructs
(along with Trans-lentiviral packaging mix plasmids) were
transfected into 293TN producer cells (System Biosciences,
Mountain View, CA), and supernatant packaged virus transduced
into AsPC-1 cells following the manufacturer’s instructions (Open
Biosystems’ Trans-lentiviral GIPZ packaging protocol). Two days
post-infection, 1 mg/ml puromycin (Invitrogen) was added to the
culture medium, and cells selected for 14 days. Anchorage
independent growth was assayed by colony formation in soft
agar. Briefly, 10,000 cells were embedded in a 6-well plate well
within a top layer of 0.36% agarose in complete media, over a
layer of 0.48% agarose in complete media. Cells were grown for
14–21 days, then visible colonies counted after staining with
0.015% Neutral Red solution. Assays were done as triplicate
transductions, and repeated at least once with similar results.
NIH-3T3 focus formation assay
Full-length human SMURF1 cDNA expression vector,
pcDNA3.1-SMURF1 was a kind gift from Di Chen (University
of Rochester Medical Center, Rochester, NY), and the parent
vector pcDNA3.1 was purchased from Invitrogen (Carlsbad, CA).
A catalytic mutant SMURF1 (C699A) [22] was engineered using
the QuickChange XL II Site-Directed Mutagenesis Kit from
Stratagene (La Jolla, CA), with the following mutagenic primers:
59-CGTGGAGGAGACCGCCGGGTTTGCTGTGG -39 (de-
Figure 5. SMURF1 overexpression in NIH-3T3 cells leads to loss
of contact inhibition. (A) Transfection of SMURF1 cDNA, or a catalytic
mutant of SMURF1 (C699A) (SMURF1
m), leads to overexpression (by
Western blot) compared to empty vector control. SMURF1 overexpres-
sion levels, normalized to GAPDH, are indicated. (B) SMURF1 (but not
SMURF1
m) overexpression in NIH-3T3 cells leads to loss of contact
inhibition (i.e. increased foci formation). Assays done in triplicate (mean
+/2 1SD shown); *, P,0.05 (Student’s t-test).
doi:10.1371/journal.pone.0023924.g005
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CAAACCCGGCGGTCTCCTCCACG-39. Fifty thousand cells
were seeded per 60 mm plate, and 8 mg of plasmid was transfected
by Lipofectamine 2000 reagent (Invitrogen) according to the
manufacturer’s protocol. Two days after transfection, cells from
each 60 mm plate were re-plated into two 10 cm plates and grown
to confluence over 28 days. Visible foci were counted after
methanol fixation and Giemsa staining. Assays were done as
triplicate transfections, and repeated at least once with similar
results.
Supporting Information
Table S1 siRNA sequences targeting SMURF1.
(PDF)
Figure S1 Hs700T cells display TGFb-induced growth
inhibition. Hs700T cells were plated, and then 2 ng/ml TGFb
(or vehicle control) added and cell proliferation/viability assayed
(by WST-1) daily. Assays were done in triplicate (mean +/2 1SD
shown); *, P,0.05; **, P,0.01; ***, P,0.001 (Student’s t-test).
Consistent with intact TGFb growth inhibition, no deletions
spanning SMAD4 (244K Agilent CGH array data; not shown) and
no point mutations of SMAD4 (Illumina RNAseq analysis; not
shown) were identified.
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